Daniel Lynch Joins Third Rock as Entrepreneur-in-Residence
This article was originally published in Scrip
Executive Summary
Daniel Lynch has joined Third Rock Ventures, a venture capital firm, as an entrepreneur-in-residence. In the role, Mr Lynch will provide strategic input on new and existing portfolio companies. Mr Lynch has 25 years' experience in management positions in the biotech and pharma industries and most recently served as CEO for ImClone Systems.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.